Previous 10 | Next 10 |
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q4 earnings results on Monday, March 1st, before market open.The consensus EPS Estimate is -$1.70 (-6.9% Y/Y) and the consensus Revenue Estimate is $1.2M (-55.1% Y/Y).Over the last 2 years, RETA has beaten EPS estimates 38% of the t...
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on ...
We have been covering mid-cap biotech concern Reata Pharmaceuticals since we recommended it at $20 in 2018. The stock is up six-fold since then and we still have a small stake in this name. There has been quite a bit of news flow around the stock since our last update on it some f...
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,00...
Reata Pharmaceuticals (RETA) has priced 2M Class A common stock at $140.85/share, for gross proceeds of $281.7M.Underwriters' over-allotment is an additional 300K Class A common stock.Offering is expected to close on December 4.Shares down 6% premarket.Previously: Reata Pharma launc...
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class...
Gainers: [[TG]] +29.6%. [[MESO]] +11.8%. [[FUBO]] +10.5%. [[VAPO]] +9.2%. [[SLQT]] +6.5%.Losers: [[OVID]] -48.7%. [[FCEL]] -16.8%. [[IRTC]] -16.1%. [[SOL]] -13.2%. [[RETA]] -9.1%. For further details see: TG, OVID, FCEL and MESO among after-hours movers
Reata Pharmaceuticals (RETA) commences a public offering of 2M shares of common stock. Price and terms have yet to be announced. For further details see: Reata Pharma launches 2M-share stock offering
Reata Pharmaceuticals (RETA) -8.8% after-hours following news that the Food and Drug Administration's review of its proposed omaveloxolone treatment for Friedreich's ataxia, a rare neuromuscular disorder, concluded that the findings do not strengthen the results of Part 2 of the MOXIe study.R...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023